Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10487MR)

This product GTTS-WQ10487MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10487MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4790MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ1738MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ12192MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ15360MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ15756MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ7179MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ13153MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ4222MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW